Cost-effectiveness of human papillomavirus vaccination among girls aged 9-16 years in China: a meta-analysis.

IF 5.5 3区医学 Q1 IMMUNOLOGY

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-06-13 DOI:10.1080/14760584.2025.2517715

Xiaoya Fu, Yilan Xia, Weiyu Zhou, Yihan Lu

{"title":"Cost-effectiveness of human papillomavirus vaccination among girls aged 9-16 years in China: a meta-analysis.","authors":"Xiaoya Fu, Yilan Xia, Weiyu Zhou, Yihan Lu","doi":"10.1080/14760584.2025.2517715","DOIUrl":null,"url":null,"abstract":"Introduction: Imported 2 v, 4 v, and 9vHPV vaccines are costly in China, whereas the domestic 2vHPV is more affordable. This study aimed to summarize cost-effectiveness evidence by pooling the incremental net monetary benefit (INB) of HPV vaccination for girls in China.Methods: We searched PubMed, Embase®, Web of Science, and Cochrane databases from inception to 18 January 2024, for cost-effectiveness analyses of 2vHPV, 4vHPV, and 9vHPV vaccines compared to no HPV vaccination (NoV) and to each other. All monetary units were adjusted to 2022 US dollars. INBs were calculated as the difference in incremental effectiveness multiplied by the willingness-to-pay threshold minus the incremental cost and pooled by vaccine type using random-effects or fixed-effects models.Results: Sixteen studies involving 61 comparisons were included. The INBs (95% CI) for domestic 2vHPV, imported 2vHPV, 4vHPV, and 9vHPV vaccines, compared to NoV, were USD 569.99 (58.62, 1081.36), 186.39 (86.21, 286.57), 239.14 (142.46, 335.81), and 298.41 (198.31, 398.51), respectively. HPV vaccines were significantly cost-effective compared to NoV. 4vHPV vaccine was less cost-effective than imported 2vHPV vaccine, with an INB of USD - 693.98 (-1062.17, -325.79).Conclusions: HPV vaccines were cost-effective compared to NoV in China. Our findings would facilitate policy-making of HPV immunization programs.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"524-534"},"PeriodicalIF":5.5000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14760584.2025.2517715","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Imported 2 v, 4 v, and 9vHPV vaccines are costly in China, whereas the domestic 2vHPV is more affordable. This study aimed to summarize cost-effectiveness evidence by pooling the incremental net monetary benefit (INB) of HPV vaccination for girls in China.

Methods: We searched PubMed, Embase®, Web of Science, and Cochrane databases from inception to 18 January 2024, for cost-effectiveness analyses of 2vHPV, 4vHPV, and 9vHPV vaccines compared to no HPV vaccination (NoV) and to each other. All monetary units were adjusted to 2022 US dollars. INBs were calculated as the difference in incremental effectiveness multiplied by the willingness-to-pay threshold minus the incremental cost and pooled by vaccine type using random-effects or fixed-effects models.

Results: Sixteen studies involving 61 comparisons were included. The INBs (95% CI) for domestic 2vHPV, imported 2vHPV, 4vHPV, and 9vHPV vaccines, compared to NoV, were USD 569.99 (58.62, 1081.36), 186.39 (86.21, 286.57), 239.14 (142.46, 335.81), and 298.41 (198.31, 398.51), respectively. HPV vaccines were significantly cost-effective compared to NoV. 4vHPV vaccine was less cost-effective than imported 2vHPV vaccine, with an INB of USD - 693.98 (-1062.17, -325.79).

Conclusions: HPV vaccines were cost-effective compared to NoV in China. Our findings would facilitate policy-making of HPV immunization programs.

查看原文本刊更多论文

中国9-16岁女孩接种人乳头瘤病毒疫苗的成本效益：一项荟萃分析

在中国，进口的2v、4v和9vHPV疫苗价格昂贵，而国产的2vHPV疫苗价格更便宜。本研究旨在通过汇总中国女孩HPV疫苗接种的增量净货币效益（INB）来总结成本效益证据。方法：我们检索PubMed， Embase®，Web of Science和Cochrane数据库，从成立到2024年1月18日，对2vHPV， 4vHPV和9vHPV疫苗与未接种HPV疫苗（NoV）的成本-效果进行分析，并相互比较。所有货币单位调整为2022美元。使用随机效应或固定效应模型计算inb，将增量有效性的差值乘以支付意愿阈值减去增量成本，并按疫苗类型汇总。结果：纳入16项研究，涉及61项比较。国产2vHPV、进口2vHPV、4vHPV和9vHPV疫苗与11月相比的inb （95%CI）分别为569.99美元（58.62、1081.36）、186.39美元（86.21、286.57）、239.14美元（142.46、335.81）和298.41美元（198.31、398.51）。4vHPV疫苗的成本效益低于进口的2vHPV疫苗，INB为- 693.98美元（-1062.17美元，-325.79美元）。结论：在中国，HPV疫苗与NoV相比具有成本效益。我们的发现将有助于制定HPV免疫规划。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Vaccines 医学-免疫学

CiteScore

9.10

自引率

3.20%

发文量

136

审稿时长

4-8 weeks

期刊介绍： Expert Review of Vaccines (ISSN 1476-0584) provides expert commentary on the development, application, and clinical effectiveness of new vaccines. Coverage includes vaccine technology, vaccine adjuvants, prophylactic vaccines, therapeutic vaccines, AIDS vaccines and vaccines for defence against bioterrorism. All articles are subject to rigorous peer-review. The vaccine field has been transformed by recent technological advances, but there remain many challenges in the delivery of cost-effective, safe vaccines. Expert Review of Vaccines facilitates decision making to drive forward this exciting field.